Journal article
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
Abstract
Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF. Compared …
Authors
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
Journal
Vascular Health and Risk Management, Vol. 10, No. 0, pp. 425–434
Publisher
Taylor & Francis
Publication Date
July 17, 2014
DOI
10.2147/vhrm.s63298
ISSN
1176-6344
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
HumansAfricaAtrial FibrillationClinical ProtocolsEuropeFactor Xa InhibitorsLatin AmericaMiddle EastMorpholinesProspective StudiesResearch DesignRisk AssessmentRisk FactorsRivaroxabanSample SizeStrokeThiophenesTime FactorsTreatment OutcomeObservational Studies as TopicClinical Trials, Phase IV as TopicMulticenter Studies as Topic